Slow and steady wins the race: practical (and philosophical) considerations of treatment activity evaluation when novel anticancer agents just slow neoplastic progression.

Authors :: Porta C
Vercelli A
Paglino C
Source :: European urology [Eur Urol] 2014 Apr; Vol. 65 (4), pp. 721-2. Date of Electronic Publication: 2013 Aug 28.
Publication Year :: 2014

Subjects :: Everolimus
Humans
Niacinamide therapeutic use
Sirolimus therapeutic use
Sorafenib
Antineoplastic Agents therapeutic use
Carcinoma, Renal Cell drug therapy
Carcinoma, Renal Cell secondary
Kidney Neoplasms drug therapy
Kidney Neoplasms pathology
Niacinamide analogs & derivatives
Phenylurea Compounds therapeutic use
Sirolimus analogs & derivatives

Full Text Access

Tools